{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T00:36:05Z","timestamp":1700267765584},"reference-count":9,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2008,3,12]],"date-time":"2008-03-12T00:00:00Z","timestamp":1205280000000},"content-version":"vor","delay-in-days":1777,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Special Care in Dentistry"],"published-print":{"date-parts":[[2003,5]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>Treatment options are limited for patients with relapsed acute myelogenous leukemia (AML), particularly when the disease is refractory to standard cytotoxic chemotherapy. Targeted drug therapy offers the advantage of delivering higher doses of non\u2010cross\u2010resistant chemotherapy with potentially less systemic toxicity. Gemtuzumab ozogamicin (Mylotarg, Wyeth\u2010Ayerst Laboratories) is an immunoconjugate that consists of humanized anti\u2010CD 33 antibody linked to the potent anti\u2010tumor antibiotic calicheamicin and has been an effective therapy for some patients with relapsed AML. However, the overall utility of gemtuzumab ozogamicin is not well defined. For instance, it is not known how well this antibody will target extramedullar\/ disease. This article reports gemtuzumab treatment of refractory AML in a 32\u2013year\u2010old man. At the time of recurrence, his bone marrow was hypoplastic and without leukemia, but the condition progressed resulting in marked leukemic infiltration of the oral mucosa. This case history raises the possibility that leukemic sanctuary sites may exist, and that monoclonal antibody therapy may have sub\u2010optimal activity in non\u2010medullary sites of disease.<\/jats:p>","DOI":"10.1111\/j.1754-4505.2003.tb01670.x","type":"journal-article","created":{"date-parts":[[2008,3,12]],"date-time":"2008-03-12T17:27:32Z","timestamp":1205342852000},"page":"108-110","source":"Crossref","is-referenced-by-count":2,"title":["Leukemic gingival infiltrate as an indicator of chemotherapeutic failure following monoclonal antibody therapy: a case report"],"prefix":"10.1111","volume":"23","author":[{"given":"Thomas P.","family":"Sollecito","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Draznin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ernesta","family":"Parisi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen","family":"Duffy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward A.","family":"Stadtmauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Selina M.","family":"Luger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen J.","family":"Schuster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donald","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David L.","family":"Porter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,3,12]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199410063311402"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199909303411407"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V67.4.1048.1048"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.2717946"},{"key":"e_1_2_1_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.13.3244"},{"key":"e_1_2_1_7_2","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1200\/JCO.1995.13.7.1800","article-title":"Extramedullar myeloid cell tumors in acute nonlymphocytic leukemia: a clinical review","volume":"13","author":"Byrd JC","year":"1995","journal-title":"J Clin"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.4.1345"},{"key":"e_1_2_1_9_2","first-page":"13","article-title":"Chemotherapy versus transplants for acute myelogenous leukemia in second remission","volume":"10","author":"Gale RP","year":"1996","journal-title":"Leukemia"},{"key":"e_1_2_1_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1754-4505.2003.tb01671.x"}],"container-title":["Special Care in Dentistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1754-4505.2003.tb01670.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1754-4505.2003.tb01670.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T05:39:55Z","timestamp":1700199595000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1754-4505.2003.tb01670.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,5]]},"references-count":9,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2003,5]]}},"alternative-id":["10.1111\/j.1754-4505.2003.tb01670.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1754-4505.2003.tb01670.x","archive":["Portico"],"relation":{},"ISSN":["0275-1879","1754-4505"],"issn-type":[{"value":"0275-1879","type":"print"},{"value":"1754-4505","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,5]]}}}